Shilpa Medicare's Q4 FY 2025-26 Quarterly Results

Result Summary

• Shilpa Medicare Ltd reported a 6.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 29.6%.
• Its expenses for the quarter were up by 7.5% QoQ and 21.6% YoY.
• The net profit increased 141.8% QoQ and increased 642.9% YoY.
• The earnings per share (EPS) of Shilpa Medicare Ltd stood at 5.51 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Shilpa Medicare Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. The company is known for its focus on research and development, particularly in the field of oncology drugs, which is a significant area of growth and innovation in pharmaceuticals. As of the latest available information, Shilpa Medicare has been expanding its portfolio through strategic partnerships and investments in state-of-the-art manufacturing facilities to enhance its production capabilities. The company operates in a competitive market, where regulatory compliance and innovation are key drivers of success. Any recent major developments within the company or specific product launches are not available in the provided data.

Revenue

For the fourth quarter of fiscal year 2026, Shilpa Medicare Ltd reported a total income of ₹438.66 crores, representing a quarter-over-quarter (QoQ) increase of 6.8% compared to the previous quarter's ₹410.54 crores. On a year-over-year (YoY) basis, the total income increased by 29.6% from ₹338.38 crores in the fourth quarter of fiscal year 2025. This growth in revenue reflects a strong performance in the company's sales and operations over the respective periods. The consistent increase in revenue suggests effective market strategies and potentially increased demand for the company's products. However, specific details regarding revenue streams or product sales contributions are not provided in the data.

Profitability

Shilpa Medicare Ltd's profitability showed substantial improvement in the fourth quarter of fiscal year 2026. The company reported a profit before tax of ₹102.13 crores, which is a significant increase of 66.9% QoQ from ₹61.21 crores and a remarkable 687.4% YoY rise from ₹12.97 crores in the same quarter of the previous year. The profit after tax for Q4FY26 was ₹107.79 crores, marking an increase of 141.8% QoQ from ₹44.58 crores and an impressive 642.9% YoY growth from ₹14.51 crores. The earnings per share (EPS) also rose to ₹5.51, up 133.5% QoQ from ₹2.36 and 272.3% YoY from ₹1.48. The data indicates a significant improvement in profitability, driven by increased operational efficiency or cost management strategies, though specific factors contributing to these results are not detailed in the provided data.

Operating Metrics

The financial data indicates that total expenses for Shilpa Medicare Ltd in Q4FY26 were ₹361.55 crores, representing a QoQ increase of 7.5% from ₹336.47 crores and a YoY increase of 21.6% from ₹297.32 crores. Despite the rise in expenses, the company managed to achieve substantial growth in profit margins. The tax expense for the quarter was ₹12.66 crores, showing a decrease of 22.2% QoQ from ₹16.27 crores, but an increase of 1544.2% YoY from ₹0.77 crores, reflecting changes in tax liabilities or accounting practices. While specific operating metrics such as production volumes or cost ratios are not provided, the data suggests effective management of operational costs relative to revenue growth. The absence of additional financial ratios such as P/E ratio or debt-to-equity ratio limits further analysis of the company's financial health and operational efficiency.